ENTEROPharmacy Retail
Entero Healthcare Solutions — Cash Flow Statement
₹1247.80
+0.05%
Entero Healthcare Solutions Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Issuance Of Debt | 0.00 | 151.50 Cr | 88.49 Cr | 143.32 Cr | — |
| Free Cash Flow | -88.18 Cr | -42.03 Cr | -50.83 Cr | -45.13 Cr | — |
| Repayment Of Debt | -45.82 Cr | -200.24 Cr | 0.00 | — | — |
| Issuance Of Capital Stock | 1.12 Cr | 1.05K Cr | 44.89 Cr | 105.63 Cr | — |
| Capital Expenditure | -11.31 Cr | -5.42 Cr | -5.52 Cr | -9.87 Cr | — |
| End Cash Position | 229.28 Cr | 147.65 Cr | 25.36 Cr | 46.51 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 12.36 Cr | 1.08 Cr | — | — | — |
| Beginning Cash Position | 147.65 Cr | 25.36 Cr | 46.51 Cr | 32.31 Cr | — |
| Changes In Cash | 69.28 Cr | 121.21 Cr | -21.15 Cr | 14.19 Cr | — |
| Financing Cash Flow | -73.66 Cr | 862.94 Cr | 72.76 Cr | 211.19 Cr | — |
| Net Other Financing Charges | -41.56 Cr | -66.09 Cr | -48.97 Cr | — | — |
| Net Preferred Stock Issuance | 0.00 | 50.98 Cr | 44.62 Cr | 101.88 Cr | — |
| Preferred Stock Issuance | 0.00 | 50.98 Cr | 44.62 Cr | 101.88 Cr | — |
| Net Common Stock Issuance | 1.12 Cr | 1.00K Cr | 0.26 Cr | 3.75 Cr | — |
| Common Stock Issuance | 1.12 Cr | 1.00K Cr | 0.26 Cr | 3.75 Cr | — |
| Net Issuance Payments Of Debt | 21.70 Cr | -98.76 Cr | 88.49 Cr | 143.32 Cr | — |
| Net Short Term Debt Issuance | 67.52 Cr | -50.02 Cr | 0.00 | — | — |
| Net Long Term Debt Issuance | -45.82 Cr | -48.74 Cr | 88.49 Cr | 143.32 Cr | — |
| Long Term Debt Payments | -45.82 Cr | -200.24 Cr | 0.00 | — | — |
| Long Term Debt Issuance | 0.00 | 151.50 Cr | 88.49 Cr | 143.32 Cr | — |
| Investing Cash Flow | 219.80 Cr | -705.12 Cr | -48.59 Cr | -161.73 Cr | — |
| Interest Received Cfi | 38.10 Cr | 9.47 Cr | 4.09 Cr | 3.44 Cr | — |
| Net Investment Purchase And Sale | 521.82 Cr | -668.09 Cr | -22.59 Cr | — | — |
| Sale Of Investment | 649.12 Cr | 0.00 | — | — | — |
| Purchase Of Investment | -127.30 Cr | -668.09 Cr | -22.59 Cr | — | — |
| Net Business Purchase And Sale | -329.75 Cr | -41.81 Cr | -24.57 Cr | -146.92 Cr | — |
| Purchase Of Business | -329.75 Cr | -41.81 Cr | -24.57 Cr | -146.92 Cr | — |
| Net PPE Purchase And Sale | -10.37 Cr | -4.69 Cr | -5.52 Cr | -9.87 Cr | — |
| Sale Of PPE | 0.94 Cr | 0.72 Cr | 0.00 | — | — |
| Purchase Of PPE | -11.31 Cr | -5.42 Cr | -5.52 Cr | -9.87 Cr | — |
| Operating Cash Flow | -76.86 Cr | -36.61 Cr | -45.31 Cr | -35.27 Cr | — |
| Taxes Refund Paid | -38.14 Cr | -13.06 Cr | -12.43 Cr | -10.90 Cr | — |
| Change In Working Capital | -221.51 Cr | -145.73 Cr | -100.36 Cr | -46.07 Cr | — |
| Change In Other Current Liabilities | -24.47 Cr | -7.11 Cr | -6.78 Cr | 30.46 Cr | — |
| Change In Other Current Assets | -44.47 Cr | -18.11 Cr | -0.29 Cr | 3.54 Cr | — |
| Change In Payable | 105.50 Cr | 1.60 Cr | 57.59 Cr | 18.52 Cr | — |
| Change In Inventory | -146.56 Cr | -58.18 Cr | -19.39 Cr | -30.10 Cr | — |
| Change In Receivables | -108.85 Cr | -66.20 Cr | -133.29 Cr | -68.49 Cr | — |
| Other Non Cash Items | 3.56 Cr | 52.35 Cr | 44.88 Cr | 25.54 Cr | — |
| Stock Based Compensation | 3.55 Cr | 1.77 Cr | 0.00 | 0.00 | — |
| Provisionand Write Offof Assets | 5.99 Cr | 7.52 Cr | 2.04 Cr | -5.99 Cr | — |
| Depreciation And Amortization | 30.69 Cr | 25.02 Cr | 24.24 Cr | 19.75 Cr | — |
| Depreciation | 30.69 Cr | 25.02 Cr | 24.24 Cr | 19.75 Cr | — |
| Gain Loss On Investment Securities | -0.96 Cr | — | — | — | — |
| Gain Loss On Sale Of PPE | 0.12 Cr | -0.04 Cr | 0.00 | — | — |
| Net Income From Continuing Operations | 138.74 Cr | 35.55 Cr | -3.69 Cr | -19.81 Cr | — |
| Interest Paid Cff | — | -66.09 Cr | -48.97 Cr | -28.98 Cr | -20.69 Cr |
| Short Term Debt Payments | — | -50.02 Cr | 0.00 | — | — |
| Amortization Cash Flow | — | 0.42 Cr | — | — | — |
| Net Other Investing Changes | — | — | -22.59 Cr | -8.38 Cr | -22.85 Cr |
| Pension And Employee Benefit Expense | — | — | 1.81 Cr | 2.21 Cr | 1.50 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Entero Healthcare Solutions
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.